Vitamin C Effectiveness in Preventing Urinary Tract Infections After Gynecological Surgeries
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT05913180 |
Recruitment Status :
Not yet recruiting
First Posted : June 22, 2023
Last Update Posted : June 22, 2023
|
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
Condition or disease | Intervention/treatment | Phase |
---|---|---|
Catheter-Associated Urinary Tract Infection | Drug: Ascorbic Acid 1000 MG Drug: Placebo | Phase 2 |
Study Type : | Interventional (Clinical Trial) |
Estimated Enrollment : | 180 participants |
Allocation: | Randomized |
Intervention Model: | Parallel Assignment |
Masking: | Double (Participant, Care Provider) |
Masking Description: | Double blinded |
Primary Purpose: | Prevention |
Official Title: | Vitamin C for the Prevention of Catheter-associated Urinary Tract Infections in Women Who Undergo Elective Gynecological Surgeries: a Randomized Double-blinded Controlled Trial |
Estimated Study Start Date : | June 15, 2023 |
Estimated Primary Completion Date : | August 15, 2025 |
Estimated Study Completion Date : | August 15, 2025 |
Arm | Intervention/treatment |
---|---|
Active Comparator: Vitamin C
1000mg Ascorbic acid daily starting the day of elective gynecological surgery for 10 days
|
Drug: Ascorbic Acid 1000 MG
1000mg Ascorbic acid orally daily started on the day of elective gynecological surgery for 10 days
Other Name: Vitamin C |
Placebo Comparator: Placebo
Placebo daily starting the day of elective gynecological surgery for 10 days
|
Drug: Placebo
Placebo tablet daily starting day of elective gynecological surgery for 10 days |
- Incidence of UTI [ Time Frame: 30 days ]The Primary endpoint is the proportion of participants who experience a clinically diagnosed and treated UTI as evidenced by a positive urine culture.
- Asymptomatic UTI [ Time Frame: 30 days ]The proportion of participants with a positive urine culture, while asymptomatic (asymptomatic bacteriuria) at the end of the study period
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study: | 18 Years to 80 Years (Adult, Older Adult) |
Sexes Eligible for Study: | Female |
Gender Based Eligibility: | Yes |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
- Nonpregnant women
- 18 years of age or older
- Undergoing elective GYN surgery
Exclusion Criteria:
- Pregnant women
- Already taking Vitamin C supplementation
- Nephrolithiasis
- Congenital anomaly or neurogenic bladder
- Allergy to ascorbic acid
- On therapeutic anticoagulant medicine during the 6 weeks after surgery
- Gynecological surgery involving fistula repair or a vaginal mesh removal
- Positive Urinalysis in the pre-admission unit
- Recurrent UTIs
- Diabetes
- G6PD
- Hemochromatosis
- Renal disorders
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT05913180
Contact: Tony Bazi, M.D. | 9611350000 | tb04@aub.edu.lb | |
Contact: George kasyan, M.D. | g.kasyan@outlook.com |
Principal Investigator: | Tony Bazi, M.D. | American University of Beirut Medical Center |
Responsible Party: | Tony Bazi, Associate Professor of Clinical Obstetrics and Gynecology, American University of Beirut Medical Center |
ClinicalTrials.gov Identifier: | NCT05913180 |
Other Study ID Numbers: |
62/137-H/77-2023-25-2295 |
First Posted: | June 22, 2023 Key Record Dates |
Last Update Posted: | June 22, 2023 |
Last Verified: | June 2023 |
Individual Participant Data (IPD) Sharing Statement: | |
Plan to Share IPD: | No |
Studies a U.S. FDA-regulated Drug Product: | No |
Studies a U.S. FDA-regulated Device Product: | No |
Product Manufactured in and Exported from the U.S.: | No |
Ascorbic acid Vitamin C Elective Gynecologic surgeries CAUTI |
Infections Communicable Diseases Urinary Tract Infections Disease Attributes Pathologic Processes Urologic Diseases Female Urogenital Diseases Female Urogenital Diseases and Pregnancy Complications Urogenital Diseases |
Male Urogenital Diseases Ascorbic Acid Vitamins Micronutrients Physiological Effects of Drugs Antioxidants Molecular Mechanisms of Pharmacological Action Protective Agents |